Commercial Opportunities

Business model and commercial strategy

illustrationPsynova Neurotech will be the vehicle for commercial exploitation of IP generated by CCNR in the field of pharmacogenomics. Value will be created by validation of key biomarkers and through the Company’s drug discovery and development programmes. In addition, the Company will exploit relevant IP created by Prof Lowe’s research into diagnostics for biomarkers identified by CCNR.

 

Psynova Neurotech may also act as a conduit through which pharmaceutical companies can access the PsyData database which comprises results from the unique collection of clinical samples assembled by Prof. Bahn and her collaborators.